{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:14:16Z","timestamp":1754162056408,"version":"3.41.2"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The optimal antithrombotic regimen for patients undergoing percutaneous coronary intervention in acute coronary syndrome with concomitant atrial fibrillation is largely under investigation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>PUBMED and EMBASE were searched through October 2019 for randomized trials or subgroup analyses of randomized trials investigating different antithrombotic strategies in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention. We compared dual antithrombotic therapy versus triple antithrombotic therapy. Dual antithrombotic therapy was defined as vitamin K antagonist or direct oral anticoagulant plus P2Y<jats:sub>12<\/jats:sub> inhibitor. Triple antithrombotic therapy was defined as vitamin K antagonist or direct oral anticoagulant plus dual antiplatelet therapy (aspirin plus P2Y<jats:sub>12<\/jats:sub> inhibitor). The primary safety outcome was trial outcome was trial defined major adverse cardiovascular events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our search identified 5 eligible subgroup analyses of randomized controlled trials that enrolled a total of 4733 patients. Dual antithrombotic therapy significantly decreased the bleeding risk when compared with triple antithrombotic therapy (hazard ratio: 0.61; 95% confidential interval [0.51\u20130.71], <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001, <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> = 31%). However, there were no significant differences in major adverse cardiovascular event between dual antithrombotic therapy versus triple antithrombotic therapy (hazard ratio: 1.08; 95% confidential interval: 0.89\u20131.31, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.44, <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> = 0%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention, dual antithrombotic therapy was associated with lower bleeding risk compared with triple antithrombotic therapy while conferring similar major adverse cardiovascular event risk. Our results should be interpreted cautiously because we did not analyze the risk of stent thrombosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000000900","type":"journal-article","created":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T19:58:43Z","timestamp":1587326323000},"page":"31-35","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention; insights from a meta-analysis"],"prefix":"10.1097","volume":"32","author":[{"given":"Toshiki","family":"Kuno","sequence":"first","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ueyama","sequence":"additional","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomo","family":"Ando","sequence":"additional","affiliation":[{"name":"Center for Interventional Vascular Therapy, Division of Cardiology, NewYork-Presbyterian Hospital\/Columbia University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Section of Heart Failure and Transplantation, University of Iowa, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMe1710753","article-title":"Triple therapy for atrial fibrillation after PCI.","volume":"377","author":"Piccini","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jacc.2014.07.957","article-title":"Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease.","volume":"64","author":"Hamon","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12928-019-00633-6","article-title":"Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective.","volume":"35","author":"Saito","year":"2020","journal-title":"Cardiovasc Interv Ther"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation.","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI.","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation.","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"R9-20250729","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials.","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.amjcard.2019.05.069","article-title":"Meta-analysis for impact of statin on mortality after transcatheter aortic valve implantation.","volume":"124","author":"Takagi","year":"2019","journal-title":"Am J Cardiol"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation.","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators.","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.","volume":"374","author":"S\u00f8rensen","year":"2009","journal-title":"Lancet"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.amjcard.2019.11.022","article-title":"Meta-analysis of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.","volume":"125","author":"Kuno","year":"2020","journal-title":"Am J Cardiol"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jcin.2013.06.015","article-title":"Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.","volume":"6","author":"Tada","year":"2013","journal-title":"JACC Cardiovascular interventions"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1161\/CIRCULATIONAHA.119.043308","article-title":"Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS trial.","volume":"140","author":"Windecker","year":"2019","journal-title":"Circulation"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10557-018-6795-9","article-title":"Ticagrelor versus clopidogrel as part of dual or triple antithrombotic therapy: a systematic review and meta-analysis.","volume":"32","author":"Andreou","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ahj.2014.07.020","article-title":"Mortality after presentation with stent thrombosis is associated with time from index percutaneous coronary intervention: a report from the VA CART program.","volume":"168","author":"Armstrong","year":"2014","journal-title":"Am Heart J"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:06:52Z","timestamp":1753812412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000900","relation":{},"ISSN":["0954-6928"],"issn-type":[{"type":"print","value":"0954-6928"}],"subject":[],"published":{"date-parts":[[2020,4,16]]}}}